공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

비소세포폐암 : 세계 의약품 예측과 시장 분석(-2029년)

Non-Small Cell Lung Cancer - Global Drug Forecast and Market Analysis to 2029

리서치사 GlobalData
발행일 2020년 12월 상품 코드 980209
페이지 정보 영문 181 Pages
가격
US $ 10,995 ₩ 12,238,000 PDF (Single User License) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 21,990 ₩ 24,477,000 PDF (Site License) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 32,985 ₩ 36,715,000 PDF (Global License) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


비소세포폐암 : 세계 의약품 예측과 시장 분석(-2029년) Non-Small Cell Lung Cancer - Global Drug Forecast and Market Analysis to 2029
발행일 : 2020년 12월 페이지 정보 : 영문 181 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계의 비소세포폐암(NSCLC) 치료제 시장을 분석했으며, 질환의 개요 및 역학적 배경, 환자 수의 동향 전망, 임상시험의 진행 상황, 출시/임상시험중인 주요 치료제, 현재 시장의 미충족 요구, 주요 기업의 개요, 전 세계/주요 8개국(미국·유럽 주요 5개국·일본·중국)의 시장 동향 전망 등을 조사하여 전해드립니다.

목차

제1장 목차

제2장 비소세포폐암(NSCLC) : 개요

제3장 서론

제4장 질환의 개요

  • 병인과 병태생리
  • 분류/병기 분류 시스템

제5장 역학

  • 질환 배경
  • 위험인자와 병존증
  • 세계의 과거 동향
  • 예측 방법
    • 이용된 정보원
    • 예측의 전제조건과 방법
    • NSCLC의 진단 발증 건수
    • NSCLC의 진단 발증 건수 : 진단시 병기별
    • NSCLC의 진단 발증 건수 : 조직형별
    • 비편평상피암·편평상피암의 진단 발증 건수 : 돌연변이의 건수
    • NSCLC의 5년 환자 수
  • 비소세포폐암(NSCLC)의 역학 예측(2019-2029년)
    • NSCLC의 진단 발증 건수
    • NSCLC의 진단 발증 건수 : 성별
    • NSCLC의 진단 발증 건수 : 연령별
    • NSCLC의 진단 발증 건수 : 진단시 병기별
    • NSCLC의 진단 발증 건수 : 조직형별
    • 비편평상피암의 진단 발증 건수 : 돌연변이별 - 게놈 바이오마커·EGFR·KRAS 돌연변이
    • 편평상피암의 진단 발증 건수 : 돌연변이별
    • NSCLC의 5년 환자 수
  • 토론
    • 역학 예측 인사이트
    • 분석의 한계
    • 분석의 강점

제6장 질병 관리

  • 진단과 치료의 개요
  • 미국
  • 유럽 주요 5개국(5EU)
  • 일본
  • 중국

제7장 경쟁 평가

  • 개요

제8장 미충족 요구와 시장 기회 평가

  • 개요
  • 종합적 분자 검사의 교육, 응용 및 개량 강화
  • 면역치료에 대한 1차 및 후천적 내성
  • 저항에 대처하기 위한 퍼스널라이즈 접근
  • 시행 가능한 돌연변이가 없는 환자를 위한 치료 옵션과 환자 결과의 개선

제9장 파이프라인 평가

  • 개요
  • 임상시험중인 유망 의약품

제10장 현재·향후 시장 참여 기업

  • 개요
  • 기업 전략의 동향
  • Merck & Co.
  • AstraZeneca
  • Roche
  • Eli Lilly
  • BMS
  • Pfizer
  • Boehringer Ingelheim
  • Novartis
  • 향후 시장 참여 기업

제11장 시장 전망

  • 세계 시장
    • 예측
    • 촉진·억제요인 : 국제적인 과제
  • 유럽 주요 5개국(5EU)
    • 예측
    • 최근의 주요 동향
    • 시장 촉진·억제요인
  • 일본
  • 미국
  • 중국

제12장 부록

KSA 21.01.14

List of Tables

List of Tables

  • Table 1: NSCLC: Key Metrics in the 8MM
  • Table 2: Histologies and Subtypes in NSCLC
  • Table 3: TNM descriptors used in the AJCC/IASLC Lung Cancer Staging System
  • Table 4: Overview of the AJCC/IASLC staging system for NSCLC.
  • Table 5: Risk Factors and Comorbidities for NSCLC
  • Table 6: 8MM, Diagnosed Incident Cases of NSCLC by Stage at Diagnosis, Ages ≥18 Years, Both Sexes, N, 2019
  • Table 7: 8MM, Diagnosed Incident Cases of Non-Squamous Cell Carcinoma by Immunotherapy and Genomic Biomarkers, Ages ≥18 Years, Both Sexes, N, 2019
  • Table 8: 8MM, Diagnosed Incident Cases of Squamous Cell Carcinoma by Mutations, Ages ≥18 Years, Both Sexes, N, 2019
  • Table 9: Biomarker Testing Rates (%) in Nonsquamous NSCLC in 2019
  • Table 10: Treatment Guidelines for NSCLC in the 8MM
  • Table 11: Country Profile - US
  • Table 12: Country Profile - 5EU
  • Table 13: Country Profile - Japan
  • Table 14: Country Profile - China
  • Table 15: Leading Treatments for NSCLC, 2019
  • Table 16: Merck's NSCLC Portfolio Assessment, 2019
  • Table 17: AstraZeneca's NSCLC Portfolio Assessment, 2019
  • Table 18: Roche's NSCLC Portfolio Assessment, 2019
  • Table 19: Eli Lilly's NSCLC Portfolio Assessment, 2019
  • Table 20: BMS's NSCLC Portfolio Assessment, 2019
  • Table 21: Pfizer's NSCLC Portfolio Assessment, 2019
  • Table 22: Boehringer Ingelheim's NSCLC Portfolio Assessment, 2019
  • Table 23: Novartis' NSCLC Portfolio Assessment, 2019
  • Table 24: Future players in NSCLC Portfolio Assessment, 2019
  • Table 25: NSCLC Market - Global Drivers and Barriers, 2019-2029
  • Table 26: Key Events Impacting Sales for NSCLC in the 5EU, 2019-2029
  • Table 27: NSCLC Market - Drivers and Barriers in the 5EU, 2019-2029
  • Table 28: Key Events Impacting Sales for NSCLC in Japan, 2019-2029
  • Table 29: NSCLC Market - Global Drivers and Barriers in Japan, 2019-2029
  • Table 30: Key Events Impacting Sales for NSCLC in the US, 2019-2029
  • Table 31: NSCLC Market - Drivers and Barriers in the US, 2019-2029
  • Table 32: Key Events Impacting Sales for NSCLC in China, 2019-2029
  • Table 33: NSCLC Market - Global Drivers and Barriers in China, 2019-2029
  • Table 34: Key Historical and Projected Launch Dates for NSCLC
  • Table 35: Key Historical and Projected Patent Expiry Dates for NSCLC
  • Table 36: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures

List of Figures

  • Figure 1: Global Sales Forecast by Country for NSCLC in 2019 and 2029
  • Figure 2: Analysis of the Company Portfolio Gap in NSCLC During the Forecast Period
  • Figure 3: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to be Licensed for the Treatment of NSCLC During the Forecast Period
  • Figure 4: 8MM, Diagnosed Incidence of NSCLC, Men, Ages ≥18 Years, 2009-2029
  • Figure 5: 8MM, Diagnosed Incidence of NSCLC, Women, Ages ≥18 Years, 2009-2029
  • Figure 6: 8MM, Sources Used and Not Used to Forecast the Diagnosed Incident Cases of NSCLC
  • Figure 7: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of NSCLC by Stage at Diagnosis
  • Figure 8: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of NSCLC by Histology Types
  • Figure 9: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of Non-Squamous Cell Carcinoma and Squamous Cell Carcinoma by PD-L1, TMB, EGFR, KRAS, BRAF V600E, and MET Exon 14 Mutations
  • Figure 10: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of Non-Squamous Cell Carcinoma Exon 18, Exon 19, Exon 20, Exon 21, KRAS G12C, KRAS G12D, KRAS G12V, ALK, BRAF, ROS1, RET, NTRK1, and HER2 Mutations
  • Figure 11: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of Squamous Cell Carcinoma by FGFR1, PIK3CA, DDR2, PTEN, ALK, ROS1, BRAF, and RET Mutations
  • Figure 12: 8MM, Sources Used to Forecast the Five-Year Diagnosed Prevalent Cases of NSCLC
  • Figure 13: 8MM, Diagnosed Incident Cases of NSCLC, Both Sexes, Ages ≥18 Years, N, 2019
  • Figure 14: 8MM, Diagnosed Incident Cases of NSCLC, by Sex, Ages ≥18 Years, N, 2019
  • Figure 15: 8MM, Diagnosed Incident Cases of NSCLC by Age, Both Sexes, N, 2019
  • Figure 16: 8MM, Diagnosed Incident Cases of NSCLC by Histological Type, Ages ≥18 Years, Both Sexes, N, 2019
  • Figure 17: 8MM, Five-Year Diagnosed Prevalent Cases of NSCLC, Ages ≥18 Years, Both Sexes, N, 2019
  • Figure 18: An Overview of the Treatment Algorithm in Non-invasive and Invasive NSCLC
  • Figure 19: The Current Paradigm for Biomarker-Driven Treatment in NSCLC
  • Figure 20: Unmet Needs and Opportunities in Non-small Cell Lung Cancer
  • Figure 21: Overview of the Development Pipeline in NSCLC
  • Figure 22: Key Phase II/III Trials for the Promising Pipeline Agents that GlobalData Expects to be Licensed for NSCLC in the 8MM During the Forecast Period
  • Figure 23: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to be Licensed for the Treatment of NSCLC During the Forecast Period
  • Figure 24: Analysis of the Company Portfolio Gap in NSCLC During the Forecast Period
  • Figure 25: Global (8MM) Sales Forecast by Country for NSCLC in 2019 and 2029
  • Figure 26: Sales Forecast by Class for NSCLC in the 5EU in 2019 and 2029
  • Figure 27: Sales Forecast by Class for NSCLC in Japan in 2019 and 2029
  • Figure 28: Sales Forecast by Class for NSCLC in the US in 2019 and 2029
  • Figure 29: Sales Forecast by Class for NSCLC in China in 2019 and 2029

Non-small cell lung cancer (NSCLC) is currently the most common cancer in the world and is the leading cause of cancer mortality in men and women. Of total lung cancer incident cases, approximately 85% are the NSCLC subtype. NSCLC patients are usually diagnosed in the later stages of the disease, resulting in a poor prognosis. Since the last global market forecast (2015-2025), there have been significant changes in the treatment of patients with advanced disease, particularly in the metastatic setting. Although NSCLC is still not considered curable, physicians are enthusiastic about the progress being made in this field. New agents provide more durable responses, as demonstrated by improvements in progression-free survival and overall survival. Progress is demonstrated by the introduction of checkpoint inhibitors into the first-line setting and multiple next-generation targeted therapeutics which have dramatically improved patient outcomes.

These recent successes will be further built upon during the forecast period. Personalized medicine will become more precise, with the development of agents targeting niche molecular aberrations, currently underserved by available treatments. Furthermore, novel agents will allow targeting of new actionable mutations. The strategic use of these targeted agents and immuno-oncology (IO)-based therapies in effective combinatorial regimens in the neoadjuvant and adjuvant settings for specific patient populations is also expected to transform the treatment landscape over the forecast period.

GlobalData is expecting the entry of the introduction of 29 novel entrants over the forecast period of 2019-2029. In this report, GlobalData has weighed the clinical and commercial potential of each NSCLC therapy to forecast market growth and identify new commercial opportunities.

KEY QUESTIONS ANSWERED

  • 29 late-stage pipeline agents are going to enter the NSCLC market from 2019 onwards. Will the impact will these agents have on the market? Which of these drugs will have the highest peak sales, and why?
  • What are the current unmet needs in NSCLC, which pipeline agents are positioned to counter these unmet needs? What are the opportunities for R&D?
  • What is the market outlook in the 8MM from 2019-2029? Considering major patent expiries, launch of new premium priced agents and expected label expansions.
  • What are the main corporate trends? Who are the current and future players?

Key Highlights

  • The main drivers of growth include the anticipated approval and launch of 29 pipeline therapies, in addition to label expansions of currently marketed therapies across the 8MM during the forecast period.
  • The main barriers to growth in the 8MM include the patent expiry of major brands and the high price of premium priced therapeutics entering the market.
  • Among the late-stage pipeline products and marketed agents, Checkpoint inhibitors and EGFR inhibitors are expected to generate the greatest revenues over the forecast period.
  • The most important unmet needs in the NSCLC market include: Comprehensive molecular testing, novel approaches to primary and acquired resistance and an improvement in curative therapeutic options

Scope

  • Overview of NSCLC including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
  • Topline NSCLC market revenue, annual cost of therapy, and major pipeline product sales in the forecast period.
  • Key topics covered include current treatment and pipeline therapies, unmet needs and opportunities, and the drivers and barriers affecting NSCLC therapeutics sales in the 8MM.
  • Pipeline analysis: Comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs (Phase III).
  • Analysis of the current and future market competition in the global NSCLC market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy

The report will enable you to -

  • Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.
  • Develop business strategies by understanding the trends shaping and driving the global NSCLC therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global NSCLC market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track drug sales in the global NSCLC therapeutics market from 2019-2029.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

1 Table of Contents

  • 1.1 List of Tables
  • 1.2 List of Figures

2 NSCLC: Executive Summary

  • 2.1 The NSCLC Market Will Expand to $32.9B in 2029
  • 2.2 Targeting Large Patient Populations in the First Line, with a Focus on Establishing New Actionable Mutations and Label Expansions for Premium Products into Earlier Lines
  • 2.3 Opportunities Remain for Tackling Primary and Acquired Resistance to Targeted and IO Based Therapies
  • 2.4 First-in-Class Approvals for Novel Actionable Mutations and Targeting Resistance
  • 2.5 What Do Physicians Think?

3 Introduction

  • 3.1 Catalyst
  • 3.2 Related Reports
  • 3.3 Upcoming Related Reports

4 Disease Overview

  • 4.1 Etiology and Pathophysiology
    • 4.1.1 Etiology
    • 4.1.2 Pathophysiology
  • 4.2 Classification or Staging Systems

5 Epidemiology

  • 5.1 Disease Background
  • 5.2 Risk Factors and Comorbidities
  • 5.3 Global and Historical Trends
  • 5.4 Forecast Methodology
    • 5.4.1 Sources Used
    • 5.4.2 Forecast Assumptions and Methods
    • 5.4.3 Diagnosed Incident Cases of NSCLC
    • 5.4.4 Diagnosed Incident Cases of NSCLC by Stage at Diagnosis
    • 5.4.5 Diagnosed Incident Cases of NSCLC by Histological Types
    • 5.4.6 Mutations Among Diagnosed Incident Cases of Non-Squamous Cell Carcinoma and Squamous Cell Carcinoma
    • 5.4.7 Five-Year Diagnosed Prevalent Cases of NSCLC
  • 5.5 Epidemiological Forecast for NSCLC, 2019-2029
    • 5.5.1 Diagnosed Incident Cases of NSCLC
    • 5.5.2 Sex-Specific Diagnosed Incident Cases of NSCLC
    • 5.5.3 Age-Specific Diagnosed Incident Cases of NSCLC
    • 5.5.4 Diagnosed Incident Cases of NSCLC by Stage at Diagnosis
    • 5.5.5 Diagnosed Incident Cases of NSCLC by Histological Type
    • 5.5.6 Diagnosed Incident Cases of Non-Squamous Cell Carcinoma by Mutations: Genomic Biomarkers, EGFR and KRAS Mutations
    • 5.5.7 Diagnosed Incident Cases of Squamous Cell Carcinoma by Mutations
    • 5.5.8 Five-Year Diagnosed Prevalent Cases of NSCLC
  • 5.6 Discussion
    • 5.6.1 Epidemiological Forecast Insight
    • 5.6.2 COVID-19 Impact
    • 5.6.3 Limitations of the Analysis
    • 5.6.4 Strengths of the Analysis

6 Disease Management

  • 6.1 Diagnosis and Treatment Overview
  • 6.2 US
  • 6.3 5EU
  • 6.4 Japan
  • 6.5 China

7 Competitive Assessment

  • 7.1 Overview

8 Unmet Needs and Opportunity Assessment

  • 8.1 Overview
  • 8.2 Increased Education, Application, and Refinement of Comprehensive Molecular Testing
  • 8.3 Primary and Acquired Resistance to Immunotherapy
  • 8.4 Personalized Approaches to Tackling Resistance
  • 8.5 Improving Curative Options and Patient Outcomes for Those Without Actionable Mutations

9 Pipeline Assessment

  • 9.1 Overview
  • 9.2 Promising Drugs in Clinical Development

10 Current and Future Players

  • 10.1 Overview
  • 10.2 Trends in Corporate Strategy
  • 10.3 Merck & Co.
  • 10.4 AstraZeneca
  • 10.5 Roche
  • 10.6 Eli Lilly
  • 10.7 BMS
  • 10.8 Pfizer
  • 10.9 Boehringer Ingelheim
  • 10.10 Novartis
  • 10.11 Future players

11 Market Outlook

  • 11.1 Global Markets
    • 11.1.1 Forecast
    • 11.1.2 Drivers and Barriers - Global Issues
  • 11.2 5EU
    • 11.2.1 Forecast
    • 11.2.2 Key Events
    • 11.2.3 Drivers and Barriers
  • 11.3 Japan
    • 11.3.1 Forecast
    • 11.3.2 Key Events
    • 11.3.3 Drivers and Barriers
  • 11.4 US
    • 11.4.1 Forecast
    • 11.4.2 Key Events
    • 11.4.3 Drivers and Barriers
  • 11.5 China
    • 11.5.1 Forecast
    • 11.5.2 Key Events
    • 11.5.3 Drivers and Barriers

12 Appendix

Back to Top
전화 문의
F A Q